Natera, Inc. $NTRA Shares Sold by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC cut its Natera stake by 33.2% in the fourth quarter, while hedge funds and other institutions still own about 99.9% of the company.
• Several insiders sold shares last quarter, including CEO Steven Leonard Chapman and CFO Michael Burkes Brophy, with total insider sales reaching 162,342 shares worth about $35.3 million.
• Natera’s recent momentum has been helped by positive product news, including Japan’s approval of Signatera for colorectal cancer and updated NCCN bladder cancer guidelines recommending ctDNA-MRD testing using Signatera technology.

Hsbc Holdings PLC lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 33.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 105,005 shares of the medical research company's stock after selling 52,264 shares during the period. Hsbc Holdings PLC owned 0.07% of Natera worth $24,170,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Reflection Asset Management purchased a new position in Natera in the fourth quarter valued at approximately $29,000. Palladiem LLC acquired a new stake in Natera during the fourth quarter worth approximately $31,000. Horizon Investments LLC purchased a new stake in shares of Natera during the 3rd quarter worth approximately $32,000. Bank of Jackson Hole Trust boosted its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company's stock valued at $37,000 after buying an additional 83 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Natera in the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 41,124 shares of the company's stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares of the company's stock, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Burkes Brophy sold 3,070 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total transaction of $594,781.80. Following the sale, the chief financial officer owned 58,291 shares of the company's stock, valued at $11,293,298.34. This trade represents a 5.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 162,342 shares of company stock valued at $35,283,396 in the last quarter. Corporate insiders own 5.05% of the company's stock.

Natera Price Performance

NTRA stock opened at $259.97 on Thursday. The company has a market cap of $37.23 billion, a price-to-earnings ratio of -159.49 and a beta of 1.56. The company has a fifty day moving average price of $210.71 and a 200 day moving average price of $215.43. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $264.65.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Japan approved Signatera for colorectal cancer, making it the first PMDA-approved MRD test in the country and opening a new international market for Natera. Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer
• Positive Sentiment: Signatera also received regulatory approval in Japan for colorectal cancer, reinforcing the significance of the launch and the potential for broader commercial traction. Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
• Positive Sentiment: Japan’s approval for Signatera has been described as a landmark win, highlighting Natera’s leadership in MRD testing and likely boosting investor confidence in the platform. Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
• Positive Sentiment: The NCCN updated bladder cancer guidelines to recommend ctDNA-MRD testing using Signatera technology, which may further validate the product and support more testing volume. NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
• Neutral Sentiment: Natera announced a partnership with Pirche to connect transplant risk assessment with Prospera monitoring, a strategic collaboration that could broaden its transplant diagnostics workflow but is less immediately material than the Signatera news. Natera (NTRA) Teams With Pirche To Link Transplant Risk And Prospera Monitoring
• Neutral Sentiment: Barclays trimmed its price target to $260 while keeping an overweight rating, which may have capped some enthusiasm but does not change the overall bullish tone. Benzinga analyst update
• Neutral Sentiment: BTIG raised its price target to $270 and reiterated a buy rating, adding another supportive analyst signal for the stock. Benzinga analyst update

Analyst Ratings Changes

NTRA has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Royal Bank Of Canada started coverage on shares of Natera in a research note on Thursday, June 11th. They issued an "outperform" rating and a $275.00 price objective for the company. Wells Fargo & Company raised their price objective on Natera from $215.00 to $220.00 and gave the stock an "equal weight" rating in a report on Friday, May 8th. Piper Sandler reissued an "overweight" rating and issued a $249.00 target price on shares of Natera in a report on Tuesday, May 12th. Finally, Barclays decreased their target price on Natera from $280.00 to $260.00 and set an "overweight" rating for the company in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $256.24.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.